

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 May 2001 (03.05.2001)

PCT

(10) International Publication Number
WO 01/30854 A2

(51) International Patent Classification⁷: **C07K 16/30**,
G01N 33/574, A61K 39/00

(21) International Application Number: PCT/SE00/02082

(22) International Filing Date: 26 October 2000 (26.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9903895-2 28 October 1999 (28.10.1999) SE

(71) Applicant (for all designated States except US): **ACTIVE BIOTECH AB** [SE/SE]; Box 724, S-220 07 Lund (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRODIN, Thomas**, N. [SE/SE]; Lidängsgatan 10, S-252 71 Råå (SE). **KARLSTRÖM, Pia**, J. [SE/SE]; Fjellievägen 10A, S-227 36 Lund (SE). **OHLSSON, Lennart**, G. [SE/SE]; Rudeboksavägen 898, S-226 55 Lund (SE). **TORDSSON, M.**, **Jesper** [SE/SE]; Flöjtavägen 20B, S-224 68 Lund (SE).

KEARNEY, Phillip, P. [AU/SE]; Kulgränden 15C, S-226 49 Lund (SE). **NILSON, Bo, H., K.** [SE/SE]; Sölvegatan 11, S-223 62 Lund (SE).


(74) Agent: **AWAPATENT AB**; Box 5117, S-200 71 Malmö (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: NOVEL COMPOUNDS



(57) Abstract: An antibody, or a derivate or a fragment thereof, having a binding structure for a target structure is described. The antibody is displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells. Said binding structure comprises the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23-33 (CDR1), 49-55 (CDR2), 88-98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158-162 (CDR1), 177-193 (CDR2), 226-238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties. There is also described a target structure displayed in, or on the surface of tumour cells, vaccine compositions, pharmaceutical compositions as well as methods related to human malignant diseases.



WO 01/30854 A2



Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.